BillionToOne Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary

BillionToOne (NASDAQ: BLLN) closed an upsized initial public offering on Nov 7, 2025, selling 5,233,765 shares of Class A common stock, which includes full exercise of the underwriters’ option for an additional 682,665 shares.

The public offering price was $60.00 per share, and the aggregate gross proceeds were approximately $314.0 million before underwriting discounts, commissions and estimated offering expenses. BillionToOne began trading on the Nasdaq Global Select Market on Nov 6, 2025 under the ticker BLLN.

Positive

• Gross proceeds of approximately $314.0 million
• Total shares sold: 5,233,765, including 682,665 additional shares

Negative

• Reported proceeds are gross; net proceeds will be lower after underwriting discounts and offering expenses
• Offering price of $60.00 per share subjects new shareholders to full post-IPO market risk

Insights

Equity Capital Markets Analyst

BillionToOne completed an upsized IPO, selling 5,233,765 Class A shares for gross proceeds of about $314.0 million.

BillionToOne closed an upsized initial public offering that included the full exercise of the underwriters' option for an additional 682,665 shares at a public offering price of $60.00 per share, generating aggregate gross proceeds of ~$314.0 million. The company's Class A common stock began trading on the Nasdaq Global Select Market on November 6, 2025, and a Form S-1 registration statement became effective on November 5, 2025.

The business mechanism is straightforward: primary equity issued at a fixed public offering price raised capital for the company while underwriters supported demand enough to exercise their full option. Key dependencies and risks are disclosure and uses of proceeds as detailed in the filed prospectus, and any post-listing dilution or selling activity described in subsequent SEC filings. Watch the filed prospectus and subsequent SEC filings for the company's stated use of proceeds and any lock-up or selling-holder schedules; near-term signals will appear in the weeks following November 6, 2025 as public filings and underwriter syndicate activity are reported.

MENLO PARK, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the closing of its upsized initial public offering of 5,233,765 shares of its Class A common stock, which includes the exercise in full of the underwriters’ option to purchase an additional 682,665 shares of Class A common stock at a public offering price of $60.00 per share, less underwriting discounts and commissions. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by BillionToOne, were approximately $314.0 million. BillionToOne’s Class A common stock began trading on the Nasdaq Global Select Market on November 6, 2025, under the ticker symbol “BLLN.”

J.P. Morgan, Piper Sandler, Jefferies and William Blair acted as joint book-running managers for the offering. Stifel, Wells Fargo Securities and BTIG also acted as book-running managers for the offering.

A registration statement on Form S-1 related to these securities has been filed with the U.S. Securities and Exchange Commission and became effective on November 5, 2025. A prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's website at www.sec.gov. The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email: prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, by telephone at (800) 747-3924, or by email at prospectus@psc.com; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at prospectus@williamblair.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BillionToOne

Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level.

Investor Contact
ir@billiontoone.com

Media Contact
billiontoone@moxiegrouppr.com

FAQ

How many shares did BillionToOne (BLLN) sell in the IPO and when did it close?

BillionToOne sold 5,233,765 shares (including 682,665 extra shares) and closed the offering on Nov 7, 2025.

What was the public offering price and total gross proceeds for BillionToOne (BLLN)?

The public offering price was $60.00 per share and aggregate gross proceeds were approximately $314.0 million.

When did BillionToOne (BLLN) begin trading on Nasdaq and under what ticker?

BillionToOne began trading on the Nasdaq Global Select Market on Nov 6, 2025 under the ticker BLLN.

Were the underwriters’ overallotment options exercised in BillionToOne’s (BLLN) IPO?

Yes, the underwriters’ option to purchase an additional 682,665 shares was exercised in full.

Are the reported proceeds for BillionToOne (BLLN) net or gross and where can the prospectus be found?

The reported $314.0 million is gross proceeds before underwriting discounts and expenses; the prospectus is available on www.sec.gov.